Compounds > arylid
Page last updated: 2024-11-05

arylid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID24326
CHEMBL ID2088012
SCHEMBL ID2169619
MeSH IDM0040105

Synonyms (25)

Synonym
arylid
4',5-dichlorosalicylanilide
ai3-50101
nsc 44167
4-chloroanilide of 5-chlorosalicylic acid
salicylanilide, 4',5-dichloro-
brn 2218448
AKOS008034892
1147-98-4
nsc-44167
nsc44167
benzamide, 5-chloro-n-(4-chlorophenyl)-2-hydroxy-
5-chloro-n-(4-chlorophenyl)-2-hydroxy-benzamide
5-chloro-n-(4-chlorophenyl)-2-hydroxybenzamide
CHEMBL2088012 ,
28d17i2dog ,
7677-99-8
unii-28d17i2dog
SCHEMBL2169619
mfcd01684526
Q27254302
bdbm50540432
DTXSID00862564
EN300-7518820
Z68152307

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" However, as antihelminthic drugs are generally designed to have low absorption when dosed orally, the very limited bioavailability of niclosamide will likely hinder its potential direct repurposing as an antiviral medication."( Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.
Chen, CZ; Chen, L; Eastman, RT; Guo, H; Hu, X; Huang, R; Huang, W; Itkin, Z; Klumpp-Thomas, C; Lee, EM; Lo, DC; Lu, X; Michael, S; Ming, GL; Shah, P; Shamim, K; Shen, M; Shinn, P; Simeonov, A; Song, H; Tang, H; Xu, M; Xu, X; Zheng, W, 2021)		0.62

Dosage Studied

ExcerptRelevanceReference
" Niclosamide's low systemic exposure when dosed orally may hinder its use to treat systemic disease."( Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
Barak, LS; Chen, M; Chen, W; Lyerly, HK; Mook, RA; Ren, XR; Spasojevic, I; Wang, J, 2015)		0.42
" However, as antihelminthic drugs are generally designed to have low absorption when dosed orally, the very limited bioavailability of niclosamide will likely hinder its potential direct repurposing as an antiviral medication."( Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.
Chen, CZ; Chen, L; Eastman, RT; Guo, H; Hu, X; Huang, R; Huang, W; Itkin, Z; Klumpp-Thomas, C; Lee, EM; Lo, DC; Lu, X; Michael, S; Ming, GL; Shah, P; Shamim, K; Shen, M; Shinn, P; Simeonov, A; Song, H; Tang, H; Xu, M; Xu, X; Zheng, W, 2021)		0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2X purinoceptor 1Homo sapiens (human)IC50 (µMol)0.19900.01922.346410.0000AID1654781
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
monoatomic ion transportP2X purinoceptor 1Homo sapiens (human)
serotonin secretion by plateletP2X purinoceptor 1Homo sapiens (human)
regulation of vascular associated smooth muscle contractionP2X purinoceptor 1Homo sapiens (human)
apoptotic processP2X purinoceptor 1Homo sapiens (human)
signal transductionP2X purinoceptor 1Homo sapiens (human)
inseminationP2X purinoceptor 1Homo sapiens (human)
regulation of blood pressureP2X purinoceptor 1Homo sapiens (human)
neuronal action potentialP2X purinoceptor 1Homo sapiens (human)
calcium-mediated signalingP2X purinoceptor 1Homo sapiens (human)
platelet activationP2X purinoceptor 1Homo sapiens (human)
response to ATPP2X purinoceptor 1Homo sapiens (human)
synaptic transmission, glutamatergicP2X purinoceptor 1Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 1Homo sapiens (human)
ceramide biosynthetic processP2X purinoceptor 1Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationP2X purinoceptor 1Homo sapiens (human)
positive regulation of calcium ion import across plasma membraneP2X purinoceptor 1Homo sapiens (human)
regulation of synaptic vesicle exocytosisP2X purinoceptor 1Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
purinergic nucleotide receptor activityP2X purinoceptor 1Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 1Homo sapiens (human)
monoatomic cation channel activityP2X purinoceptor 1Homo sapiens (human)
protein bindingP2X purinoceptor 1Homo sapiens (human)
ATP bindingP2X purinoceptor 1Homo sapiens (human)
identical protein bindingP2X purinoceptor 1Homo sapiens (human)
suramin bindingP2X purinoceptor 1Homo sapiens (human)
protein-containing complex bindingP2X purinoceptor 1Homo sapiens (human)
ligand-gated calcium channel activityP2X purinoceptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneP2X purinoceptor 1Homo sapiens (human)
external side of plasma membraneP2X purinoceptor 1Homo sapiens (human)
secretory granule membraneP2X purinoceptor 1Homo sapiens (human)
specific granule membraneP2X purinoceptor 1Homo sapiens (human)
membrane raftP2X purinoceptor 1Homo sapiens (human)
postsynaptic membraneP2X purinoceptor 1Homo sapiens (human)
presynaptic active zone membraneP2X purinoceptor 1Homo sapiens (human)
glutamatergic synapseP2X purinoceptor 1Homo sapiens (human)
protein-containing complexP2X purinoceptor 1Homo sapiens (human)
plasma membraneP2X purinoceptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID1762033Inhibition of NS-1in Zika virus2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.
AID684292Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 14 days by micromethod2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis and in vitro antimycobacterial activity of 2-methoxybenzanilides and their thioxo analogues.
AID1180437Antimycobacterial activity against Isoniazid, rifampicin, ofloxacin and ethambutol-resistant Mycobacterium avium 330/88 assessed as complete growth inhibition after 21 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1180441Antimycobacterial activity against clinical isolate Mycobacterium kansasii 6509/96 assessed as complete growth inhibition after 7 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID775554Antimycobacterial activity against Mycobacterium smegmatis ATCC 700084 after 3 days2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species.
AID775560Antimicrobial activity against Bacillus cereus ATCC 14579 after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species.
AID684293Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 21 days by micromethod2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis and in vitro antimycobacterial activity of 2-methoxybenzanilides and their thioxo analogues.
AID1180459Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Trichophyton mentagrophytes 4452014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID775556Antimicrobial activity against Clostridium perfringens CNCTC 5770 after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species.
AID775557Antimicrobial activity against methicillin-resistant Staphylococcus aureus 3202 after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species.
AID1180456Selectivity index, ratio of IC50 for human HepG2 cells to MIC for atypical mycobacteria2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1654781Antagonist activity at non-desensitizing human P2X1 receptor ( P2X2/P2X1 chimera) expressed in human 1321N1 cells assessed as inhibition of ATP-induced calcium influx pre-incubated for 30 mins before ATP stimulation by FLIPR assay relative to control2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists.
AID1762035Metabolic stability in rat liver microsomes2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.
AID1180442Antimycobacterial activity against clinical isolate Mycobacterium kansasii 6509/96 assessed as complete growth inhibition after 14 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID775559Antimicrobial activity against methicillin-resistant Staphylococcus aureus 63718 after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species.
AID1241255Inhibition of Wnt/beta-catenin in human U2OS cells assessed as internalization of frizzled-GFP at 12.5 uM after 6 hrs by confocal microscopic analysis2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
AID775558Antimicrobial activity against methicillin-resistant Staphylococcus aureus 630 after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species.
AID1241256Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
AID775555Antimicrobial activity against Pasteurella multocida clinical isolate after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species.
AID684289Antimycobacterial activity against Mycobacterium avium My 330/88 after 14 days by micromethod2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis and in vitro antimycobacterial activity of 2-methoxybenzanilides and their thioxo analogues.
AID775552Antimycobacterial activity against Mycobacterium kansasii DSM 44162 after 7 days2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species.
AID1180455Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1180438Antimycobacterial activity against Mycobacterium kansasii 235/80 assessed as complete growth inhibition after 7 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID684287Antimycobacterial activity against Mycobacterium tuberculosis My 331/88 after 14 days by micromethod2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis and in vitro antimycobacterial activity of 2-methoxybenzanilides and their thioxo analogues.
AID684288Antimycobacterial activity against Mycobacterium tuberculosis My 331/88 after 21 days by micromethod2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis and in vitro antimycobacterial activity of 2-methoxybenzanilides and their thioxo analogues.
AID775553Antimycobacterial activity against Mycobacterium marinum CAMP 5644 after 21 days2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species.
AID1180444Inhibition of Mycobacterium tuberculosis H37Rv isocitrate lyase assessed as glyoxylate phenyl hydrazone formation at 10 uM2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID775561Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by broth microdilution method2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species.
AID1180443Antimycobacterial activity against clinical isolate Mycobacterium kansasii 6509/96 assessed as complete growth inhibition after 21 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID684290Antimycobacterial activity against Mycobacterium avium My 330/88 after 21 days by micromethod2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis and in vitro antimycobacterial activity of 2-methoxybenzanilides and their thioxo analogues.
AID1762034Inhibition of envelope protein in Zika virus2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.
AID1180439Antimycobacterial activity against Mycobacterium kansasii 235/80 assessed as complete growth inhibition after 14 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1180434Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 assessed as complete growth inhibition after 14 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1654779Antagonist activity at non-desensitizing human P2X1 receptor ( P2X2/P2X1 chimera) expressed in human 1321N1 cells assessed as inhibition of ATP-induced calcium influx at 10 uM pre-incubated for 30 mins before ATP stimulation by FLIPR assay relative to con2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists.
AID1180435Antimycobacterial activity against Mycobacterium tuberculosis H37Rv 331/88 assessed as complete growth inhibition after 21 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1180460Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Mycobacterium tuberculosis H37Rv2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1180436Antimycobacterial activity against Isoniazid, rifampicin, ofloxacin and ethambutol-resistant Mycobacterium avium 330/88 assessed as complete growth inhibition after 14 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1180440Antimycobacterial activity against Mycobacterium kansasii 235/80 assessed as complete growth inhibition after 21 days2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.
AID1762036Permeability of compound by PAMPA assay2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.
AID1762037Solubility of the compound2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (57.14)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.32 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-nitropropionic acid
3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE. 3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.		2.4920C-nitro compoundantimycobacterial drug;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
mycotoxin;
neurotoxin
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.0810aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		2.110conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.7830carbohydrazideantitubercular agent;
drug allergen
niclosamide
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.		2.5820benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
aminosalicylic acid
Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.		2.110aminobenzoic acid;
phenols		antitubercular agent
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert. 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.		2.2510arenesulfonic acid;
azobenzenes;
methylpyridines;
monohydroxypyridine;
organic phosphate;
pyridinecarbaldehyde		purinergic receptor P2X antagonist
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		2.110penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		2.0810beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
salicylanilide
salicylanilide: RN given refers to parent cpd. salicylanilide : An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide.		2.110benzanilide fungicide;
salicylamides;
salicylanilides
imd 0354
N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source		2.2510benzamides
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.110antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
nf 449
[no description available]		2.2510
ConditionIndicatedRelationship StrengthStudiesTrials